Pretreatment ctDNA Predicts Survival in Non-Small Cell Lung Cancer
PD-L1 expression and tumor mutational burden were not associated with survival.
IASLC
Global Impact of COVID-19 on Enrollment in Lung Cancer Trials
Enrollment declined 43% from 2019 to 2020.
Socioeconomic Status Does Not Predict Survival in Mesothelioma
Factors associated with poor survival were advanced age and male sex.
Lurbinectedin Plus Doxorubicin Improves PFS, Not OS, in Small-Cell Lung Cancer
The 12-month progression-free survival rate was superior in the lurbinectedin arm.
Adding Immunotherapy to Chemo Improves Survival in Metastatic Non-Small Cell Lung Cancer
The combinations conferred benefits in nonsquamous non-small cell lung cancer only.
Study Reveals Shorter Time to Lung Cancer Treatment During COVID-19 Pandemic
The time from cytohistological diagnosis to treatment initiation was longer in 2019 than in 2020.
Lung Cancer Patients Have Lower Antibody Response to COVID-19 Vaccination
Researchers are evaluating whether specific anticancer therapies affect antibody levels.
Type of Surgery and Surgical Pathway Tied to Risk of Perioperative COVID-19 in Non-Small Cell Lung Cancer
Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.
Pembrolizumab Shows Overall Survival Benefit at 3 Years in Advanced NSCLC
KEYNOTE-024 shows first-line pembrolizumab has long-term overall survival benefit in patients with advanced non-small cell lung cancer and PD-L1–expressing disease.
Long-Term OS Benefit for Nivolumab Vs Docetaxel in Previously Treated Patients With Advanced NSCLC: A Pooled Analysis
Although historically, the 5-year OS rate for patients with advanced NSCLC treated with chemotherapy is less than 5%, patients treated with nivolumab had a 5-year OS of 13.4%.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in IASLC/WCLC 2019
Loading... 
Loading...